Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 01:05PM ET
1.58
Dollar change
0.00
Percentage change
0.00
%
Index- P/E- EPS (ttm)-0.52 Insider Own1.98% Shs Outstand227.17M Perf Week17.91%
Market Cap358.93M Forward P/E- EPS next Y-0.47 Insider Trans-3.56% Shs Float222.66M Perf Month-1.86%
Income-114.08M PEG- EPS next Q-0.09 Inst Own62.39% Short Float1.40% Perf Quarter119.75%
Sales60.69M P/S5.91 EPS this Y-327.78% Inst Trans-0.52% Short Ratio1.65 Perf Half Y97.50%
Book/sh0.17 P/B9.08 EPS next Y-23.38% ROA-37.31% Short Interest3.11M Perf Year49.06%
Cash/sh0.65 P/C2.44 EPS next 5Y1.00% ROE-187.96% 52W Range0.42 - 2.05 Perf YTD99.24%
Dividend Est.- P/FCF- EPS past 5Y10.30% ROI-192.17% 52W High-22.93% Beta2.38
Dividend TTM- Quick Ratio2.85 Sales past 5Y134.88% Gross Margin83.77% 52W Low276.19% ATR (14)0.17
Dividend Ex-Date- Current Ratio2.85 EPS Y/Y TTM48.98% Oper. Margin-250.53% RSI (14)58.01 Volatility11.05% 12.39%
Employees449 Debt/Eq0.64 Sales Y/Y TTM123.93% Profit Margin-187.98% Recom2.14 Target Price3.50
Option/ShortYes / Yes LT Debt/Eq0.50 EPS Q/Q-18.55% Payout- Rel Volume0.64 Prev Close1.58
Sales Surprise-99.11% EPS Surprise75.76% Sales Q/Q-97.90% EarningsMar 06 BMO Avg Volume1.88M Price1.58
SMA203.98% SMA5023.96% SMA20081.46% Trades Volume690,783 Change0.00%
Date Action Analyst Rating Change Price Target Change
Mar-24-23Initiated Bryan Garnier Buy $3.60
Jan-03-23Upgrade Guggenheim Neutral → Buy $5
Nov-09-22Upgrade Mizuho Neutral → Buy $9
May-28-21Initiated Barclays Underweight $4
Apr-22-20Initiated Mizuho Neutral $3
Aug-02-19Downgrade Guggenheim Buy → Neutral
May-31-19Initiated ROTH Capital Buy
May-30-19Resumed Citigroup Buy
May-07-19Downgrade SVB Leerink Outperform → Mkt Perform $12 → $5
Mar-17-17Initiated Wells Fargo Market Perform
Mar-27-24 07:30PM
Mar-07-24 01:42PM
08:24AM
Mar-06-24 12:52PM
07:00AM
08:00AM Loading…
Feb-27-24 08:00AM
Feb-21-24 04:00PM
Feb-16-24 03:57AM
Feb-13-24 06:15PM
Jan-31-24 04:44PM
Jan-30-24 01:02PM
Jan-16-24 11:17AM
Jan-04-24 07:37AM
Dec-06-23 07:00AM
Nov-30-23 10:52AM
08:00AM Loading…
Nov-29-23 08:00AM
Nov-13-23 09:35AM
08:35AM
Nov-08-23 07:30AM
07:05AM
Nov-07-23 06:15PM
Oct-31-23 08:00AM
08:00AM
Oct-27-23 06:15PM
Oct-25-23 08:06AM
Oct-23-23 04:15AM
Sep-11-23 08:00AM
Aug-09-23 07:29AM
Aug-03-23 01:24PM
Jul-28-23 12:30PM
07:28AM Loading…
Jul-20-23 07:28AM
Jul-16-23 08:18PM
Jun-29-23 09:18AM
Jun-26-23 11:23AM
11:15AM
Jun-23-23 09:15AM
Jun-22-23 09:40AM
Jun-19-23 10:18AM
Jun-16-23 08:39AM
Jun-15-23 09:43AM
08:18AM
Jun-13-23 10:14AM
Jun-12-23 10:00AM
09:48AM
Jun-09-23 10:52AM
Jun-06-23 06:50AM
Jun-05-23 11:40AM
10:22AM
Jun-01-23 03:29PM
May-30-23 09:35AM
May-25-23 05:00PM
May-12-23 07:29AM
May-09-23 06:43AM
May-05-23 05:00AM
Apr-28-23 12:00PM
Apr-18-23 11:49AM
Apr-12-23 10:42AM
Apr-11-23 12:13PM
08:00AM
Mar-08-23 07:14AM
05:23AM
Mar-06-23 01:08PM
06:30AM
06:00AM
Feb-22-23 08:00AM
Feb-16-23 08:00AM
Jan-09-23 08:00AM
Jan-08-23 07:06AM
Dec-28-22 06:51AM
Dec-27-22 09:05AM
Dec-23-22 01:20PM
Dec-10-22 09:02AM
Nov-18-22 08:00AM
Nov-13-22 07:28AM
Nov-11-22 10:52AM
Nov-10-22 06:03AM
Nov-08-22 03:11PM
09:41AM
07:30AM
07:00AM
Oct-27-22 12:27PM
Oct-25-22 11:12AM
08:00AM
Sep-09-22 10:23AM
07:00AM
Aug-25-22 08:00AM
Aug-10-22 06:27AM
Aug-04-22 07:30AM
Aug-01-22 06:21AM
Jul-21-22 08:00AM
Jul-01-22 04:45PM
11:10AM
Jun-27-22 03:27PM
Jun-01-22 10:17AM
May-26-22 05:00PM
May-17-22 05:03PM
May-16-22 05:00PM
May-09-22 07:30AM
May-04-22 08:00AM
Apr-28-22 04:30PM
Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rawcliffe AdrianChief Executive OfficerJan 17 '24Sale0.6730,08020,24444,848Jan 17 05:31 PM
Bertrand William C JRChief Operating OfficerJan 17 '24Sale0.6718,90812,7257,785Jan 17 05:30 PM
Norry ElliotChief Medical OfficerJan 17 '24Sale0.6718,27612,3007,785Jan 17 05:31 PM
Lunger JohnChief Patient Supply OfficerJan 17 '24Sale0.6718,11412,1917,785Jan 17 05:30 PM
Rawcliffe AdrianChief Executive OfficerJan 16 '24Sale0.799,3047,35014,104Jan 17 05:31 PM
Lunger JohnChief Patient Supply OfficerJan 16 '24Sale0.794,6813,6987,023Jan 17 05:30 PM
Bertrand William C JRChief Operating OfficerJan 16 '24Sale0.794,6813,6987,023Jan 17 05:30 PM
Norry ElliotChief Medical OfficerJan 16 '24Sale0.792,2871,8073,363Jan 17 05:31 PM
Rawcliffe AdrianChief Executive OfficerJan 12 '24Sale0.8517,25714,73926,388Jan 12 05:00 PM
Norry ElliotChief Medical OfficerJan 12 '24Sale0.857,7996,66111,841Jan 12 05:00 PM
Bertrand William C JRChief Operating OfficerJan 12 '24Sale0.855,2204,4587,874Jan 12 05:00 PM
Lunger JohnChief Patient Supply OfficerJan 12 '24Sale0.855,2204,4587,874Jan 12 05:00 PM
Rawcliffe AdrianChief Executive OfficerJan 11 '24Sale0.8411,9459,99418,395Jan 12 05:00 PM
Lunger JohnChief Patient Supply OfficerJan 11 '24Sale0.844,0093,3546,104Jan 12 05:00 PM
Bertrand William C JRChief Operating OfficerJan 11 '24Sale0.844,0093,3546,104Jan 12 05:00 PM
Norry ElliotChief Medical OfficerJan 11 '24Sale0.844,0093,3546,104Jan 12 05:00 PM
Rawcliffe AdrianChief Executive OfficerSep 01 '23Sale0.782,4031,8743,449Sep 01 07:00 PM
Lunger JohnChief Patient Supply OfficerAug 01 '23Sale0.913,0962,8044,718Aug 01 05:00 PM
Menzel Garry EDirectorJul 10 '23Sale0.9147,70243,44775,056Jul 10 05:01 PM
Rawcliffe AdrianChief Executive OfficerJun 27 '23Sale0.922,3332,1463,519Jun 27 09:15 PM